About our Retinal Diseases efforts
The ambition to prevent vision loss in people at risk, and preserve or restore vision in those with retinal diseases, is at the core of our R&D activities. Our extensive knowledge and insights from other therapeutic areas enable us to tackle the multifactorial pathophysiology of retinal diseases. Areas of focus include wet age-related macular degeneration, diabetic retinopathy and geographic atrophy.
Selection of projects in February 2024
Phase 1 studies are usually designed with an emphasis on the assessment of safety and tolerability of an investigational drug in a small group of people for the first time. It can include healthy participants or participants with the disease.
Phospholipid modulator
Vascular modulator
C3-binding polypeptide
Phase 2 studies are usually designed to begin to evaluate the efficacy of an investigational drug in a higher number of participants with the disease, and often used to obtain dose-ranging information. Safety also continues to be assessed during this phase.
BI 764524
Indication abbreviation
DR: Diabetic retinopathy
Related Press Releases
Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy, a Leading Cause of Blindness Worldwide
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
